文献速递心力衰竭与心肌病血脂与心血管预防

SGLT-2抑制剂与其他降糖药相比降低心衰和死亡风险:CVD-REAL研究

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
PubMed 文献 · Circulation · 2017-05-18

CVD-REAL研究在6个国家纳入309 056例新起始降糖治疗的患者,经倾向评分匹配后比较SGLT-2抑制剂与其他降糖药。SGLT-2抑制剂组心衰住院风险(HR 0.61)、死亡风险(HR 0.49)及心衰住院或死亡复合风险(HR 0.54)均显著降低,提示获益可能为类效应。

要点

  • SGLT-2抑制剂组心衰住院风险较其他降糖药组降低(HR 0.61)。
  • SGLT-2抑制剂组死亡风险较其他降糖药组降低(HR 0.49)。
  • 心衰住院或死亡复合风险HR 0.54,各国间无显著异质性。

核心结论

  • 在多国真实世界人群中,SGLT-2抑制剂治疗与其他降糖药相比与较低的心衰住院和死亡风险相关。
  • 恩格列净在随机试验中的获益可能为适用于广泛2型糖尿病患者的类效应。

研究设计与样本

  • 多国观察性比较效果研究,数据来自美国、挪威、丹麦、瑞典、德国和英国的医疗索赔、初级保健/医院记录及国家登记。
  • 采用倾向评分匹配SGLT-2抑制剂起始组与其他降糖药组,按国家估算风险比并合并加权效应量。
  • 匹配后共309 056例新起始降糖治疗患者,每组154 528例;德国无死亡数据。

主要发现

  • SGLT-2抑制剂组心衰住院风险较其他降糖药组降低(HR 0.61;95%CI 0.51-0.73;P<0.001)。
  • SGLT-2抑制剂组死亡风险较其他降糖药组降低(HR 0.49;95%CI 0.41-0.57;P<0.001)。
  • SGLT-2抑制剂组心衰住院或死亡复合风险较其他降糖药组降低(HR 0.54;95%CI 0.48-0.60;P<0.001),各国间无显著异质性。
  • 随访190 164人年期间共961例心衰住院(发生率0.51/100人年)。
  • 美国、挪威、丹麦、瑞典和英国共215 622例患者中,死亡1334例(发生率0.87/100人年),心衰住院或死亡1983例(发生率1.38/100人年)。

关键数值与推荐

  • SGLT-2抑制剂组中卡格列净、达格列净和恩格列净分别占总暴露时间的53%、42%和5%。

临床怎么用

  • 在真实世界2型糖尿病患者中,起始SGLT-2抑制剂与其他降糖药相比与较低的心衰住院和死亡风险相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) empagliflozin in patients with type 2 diabetes mellitus who have atherosclerotic cardiovascular disease. We compared HHF and death in patients newly initiated on any SGLT-2i versus other glucose-lowering drugs in 6 countries to determine if these benefits are seen in real-world practice and across SGLT-2i class. METHODS: Data were collected via medical claims, primary care/hospital records, and national registries from the United States, Norway, Denmark, Sweden, Germany, and the United Kingdom. Propensity score for SGLT-2i initiation was used to match treatment groups. Hazard ratios for HHF, death, and their combination were estimated by country and pooled to determine weighted effect size. Death data were not available for Germany. RESULTS: After propensity matching, there were 309 056 patients newly initiated on either SGLT-2i or other glucose-lowering drugs (154 528 patients in each treatment group). Canagliflozin, dapagliflozin, and empagliflozin accounted for 53%, 42%, and 5% of the total exposure time in the SGLT-2i class, respectively. Baseline characteristics were balanced between the 2 groups. There were 961 HHF cases during 190 164 person-years follow-up (incidence rate, 0.51/100 person-years). Of 215 622 patients in the United States, Norway, Denmark, Sweden, and the United Kingdom, death occurred in 1334 (incidence rate, 0.87/100 person-years), and HHF or death in 1983 (incidence rate, 1.38/100 person-years). Use of SGLT-2i, versus other glucose-lowering drugs, was associated with lower rates of HHF (hazard ratio, 0.61; 95% confidence interval, 0.51-0.73; P<0.001); death (hazard ratio, 0.49; 95% confidence interval, 0.41-0.57; P<0.001); and HHF or death (hazard ratio, 0.54; 95% confidence interval, 0.48-0.60; P<0.001) with no significant heterogeneity by country. CONCLUSIONS: In this large multinational study, treatment with SGLT-2i versus other glucose-lowering drugs was associated with a lower risk of HHF and death, suggesting that the benefits seen with empagliflozin in a randomized trial may be a class effect applicable to a broad population of patients with type 2 diabetes mellitus in real-world practice. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02993614.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kosiborod M, Cavender MA, Fu AZ, et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017. PMID: 28522450. doi:10.1161/CIRCULATIONAHA.117.029190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。